First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study

First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study

Background: Aminopeptidase N (CD13) is present on tumor vasculature cells and some tumor cells. Truncated tissue factor (tTF) with a C-terminal NGR-peptide (tTF-NGR) binds to CD13 and causes tumor vascular thrombosis with infarction. Methods: We treated 17 patients with advanced cancer beyond standa...

Full description

Bibliographic Details
Main Authors: Christoph Schliemann, Mirjam Gerwing, Hauke Heinzow, Saliha Harrach, Christian Schwöppe, Moritz Wildgruber, Anna A. Hansmeier, Linus Angenendt, Andrew F. Berdel, Ursula Stalmann, Björna Berning, Karsten Kratz-Albers, Kristina Middelberg-Bisping, Stefanie Wiebe, Jörn Albring, Christian Wilms, Wolfgang Hartmann, Eva Wardelmann, Tobias Krähling, Walter Heindel, Joachim Gerss, Eike Bormann, Hartmut Schmidt, Georg Lenz, Torsten Kessler, Rolf M. Mesters, Wolfgang E. Berdel
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
tTF-NGR
vascular targeting
CD13
aminopeptidase N
first-in-class phase I study
Online Access:https://www.mdpi.com/2072-6694/12/6/1488

Internet

https://www.mdpi.com/2072-6694/12/6/1488

Similar Items